Eloxx Pharmaceuticals has dosed the first two patients in its Phase 2b EXACT study testing exaluren for nonsense mutation Alport syndrome (NMAS), a rare genetic kidney disease with no FDA-approved treatments. The trial will evaluate the drug's safety and efficacy in 24 patients, with topline data from the initial 16-week placebo-controlled phase expected by mid-2027 and final results by the end of 2027. Exaluren aims to address the genetic cause by promoting production of functional protein, offering hope for patients who often face kidney failure by their twenties.
Ether's price surged 7.46% to $2619 following US inflation data showing 3.4% annual growth, in line with expectations. This triggered a relief rally as investors reacted positively to the absence of worse inflation news, with short sellers buying bac...
Revolut disclosed personal and financial data of some customers, including Bitcoin transaction histories, following a request that appeared to be from a legitimate government agency but was sent from an unauthorized email account. The exposed informa...
Fetch.ai has introduced the A2A Outbound Adapter, enabling its autonomous AI agents to communicate easily with external agents using the Google-linked A2A Protocol. This tool supports single or multiple server connections and includes features like a...
Titan Minerals reported new drilling results at its Dynasty Gold Project in Ecuador, including a 16-meter intercept at 2.8 g/t gold and 9.1 g/t silver extending mineralisation beyond the current resource. The company is expanding its drilling program...
Alkane Resources reported resource growth at its three producing mines—Björkdal, Tomingley, and Costerfield—during the 2026 financial year by replacing depletion through exploration. The updated inventory includes 8.64 million ounces of gold in measu...
